Estudo de caso sobre o licenciamento compulsório do Efavirenz: uma análise crítica à luz do Acordo TRIPS

Abstract

The compulsory licensing of Efavirenz by Brazil was an unprecedented event in the Americas. On the one hand, Non-Governmental Organizations, activists and HIV-positive people applauded the measure, while on the other, pharmaceutical multinationals and the governments of several countries, especially the United States, expressed dissatisfaction, claiming that the measure was unnecessary. The compulsory licensing of Efavirenz was declared in 2007, in response to the serious HIV/AIDS epidemic that had been ravaging the world since the 1980s, raising concerns about the sustainability of treatment programs and the continuity of drug supplies, especially in undeveloped countries. At the time, Brazil already had an internationally recognized policy to combat HIV/AIDS, and its laws to support people living with AIDS and the free distribution of antiretroviral drugs showed that the country was willing to negotiate and, if necessary, adopt extreme measures, as in fact happened. In this context, this study aims to analyze the compulsory licensing of Efavirenz in the light of the TRIPS Agreement, identifying the reasons and grounds that Brazil used to justify this decision. To achieve this goal, the study begins with an analysis of Intellectual Property, going through the patent system and its challenges in the current Brazilian scenario, identifying the gaps left by TRIPS, and addressing how its flexibilities impact on the Brazilian legal system. In order to understand the seriousness of the situation and assess the plausibility of the measure, official statistical data is examined, as well as the historical context in which the licensing took place. In addition, the study investigates the legislative updates that have proved necessary to harmonize theory with real practical needs, addressing prevention strategies currently used and how they aim to combat HIV infection. Finally, critical considerations are presented on the compulsory licensing of Efavirenz, assessing the implications and consequences of this measure both on the international stage and in Brazilian public health policy.